McKinsey Finds Global Business Leaders Most Worried About Geopolitics, China Slowdown

India Share of APAC Private Capital Up

Growing geopolitical tensions and a slowing Chinese economy are among the topmost concerns for global business leaders across sectors, a McKinsey study has shown. Separately, in pharma, the BIOSECURE Act continues to occupy centre stage with US House Speaker Johnson recently pledging to push China-targeted legislation before House elections in November

McKinsey logo
McKinsey Points To Geopolitical Concerns, Digital Divide, Capital Reallocation • Source: Shutterstock

To effectively steer a company, business leaders must keep an eye on external factors, including global geopolitical and socio-economic trends that could impact business, and leaders in the biopharma industry are no exception.

A McKinsey & Co survey of over 1,000 business leaders globally, across sectors, on potential risks to economic growth identified geopolitical instability and/or conflicts,

More from Business

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.